Open access
Open access
Powered by Google Translator Translator

Oncology – Skin

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma

1 Aug, 2023 | 14:24h | UTC

Part 1: Diagnostics and prevention – European Journal of Cancer

Part 2: Treatment – European Journal of Cancer

 


Phase 2 Trial | Nivolumab shows promise as adjuvant therapy in completely resected Merkel cell carcinoma

20 Jul, 2023 | 11:02h | UTC

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Adjuvant Nivolumab vs Observation for Patients With Completely Resected Merkel Cell Carcinoma – The ASCO Post

 


RCT | Microdosed incisional clindamycin reduces infection rate in skin cancer surgery

30 May, 2023 | 12:03h | UTC

Effect of Microdoses of Incisional Antibiotics on the Rate of Surgical Site Infections in Skin Cancer Surgery: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)

See also: Visual Abstract

Commentary: Microdosed Incisional Clindamycin Cuts SSI After Skin Cancer Surgery – HealthDay

 


Cohort Study | 5-mm margins may be adequate for T1a melanoma excision near critical structures

16 May, 2023 | 14:40h | UTC

Association of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures – JAMA Dermatology (link to abstract – $ for full-text)

Commentary: Melanoma Excisions with 5 Millimeter Margins Linked to Less Risk of Local Recurrence – HCP Live

 

Commentary on Twitter

 


Clinical Trial Update | Nivolumab plus Relatlimab for advanced melanoma fail to reach OS threshold despite PFS improvement

25 Apr, 2023 | 14:25h | UTC

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma – NEJM Evidence

Original Study: Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine

 

Commentary on Twitter

 


USPSTF Statement | There is insufficient evidence to guide skin cancer screening recommendations

24 Apr, 2023 | 14:07h | UTC

Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement – JAMA

Evidence Report: Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

Editorials:

The USPSTF I Statement on Skin Cancer Screening—Not a Disappointment but an Opportunity – JAMA Dermatology

Skin Cancer Screening: The Importance of Identifying High-risk Subgroups and the Need for US-Based Population Research – JAMA

Insufficient Evidence for Screening Reinforces Need for Primary Prevention of Skin Cancer – JAMA Internal Medicine

Patient Page: Screening and Prevention of Skin Cancer – JAMA

Author Interview: USPSTF Recommendation: Screening for Skin Cancer – JAMA

 

Commentary on Twitter

 


S1-guideline cutaneous and subcutaneous leiomyosarcoma

4 Apr, 2023 | 13:37h | UTC

S1-guideline cutaneous and subcutaneous leiomyosarcoma – Journal of the German Dermatology Society

 


Guideline | Merkel cell carcinoma

23 Mar, 2023 | 12:48h | UTC

S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022 – Journal of the German Society of Dermatology

 


Suggested guidelines for the treatment of mycosis fungoides in countries with limited resources

21 Mar, 2023 | 13:29h | UTC

Suggested Guidelines for the Treatment of Mycosis Fungoides in Countries with Limited Resources – Dermatology Research and Practice

 


Guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease)

21 Mar, 2023 | 13:27h | UTC

British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022 – British Journal of Dermatology

 


FDA issues new information on cases of squamous cell carcinoma and lymphomas around breast implants

16 Mar, 2023 | 13:28h | UTC

Summary: The US Food and Drug Administration (FDA) has provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue (capsule) that forms around breast implants. The FDA is aware of 19 cases of SCC in the capsule around the breast implant from published literature, including 3 reports of deaths from the disease.

While the FDA continues to believe that occurrences of SCC in the capsule around the breast implant may be rare, the cause, incidence, and risk factors remain unknown. Health care providers and people who have or are considering breast implants should be aware that cases of SCC and various lymphomas in the capsule around the breast implant have been reported to the FDA and in the literature.

The FDA continues to ask health care providers and people with breast implants to report cases of SCC, lymphomas, or any other cancers around breast implants.

FDA Safety Communication: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants – FDA Safety Communication – U.S. Food & Drug Administration

Commentary: FDA Issues Safety Communication on Reports of Squamous Cell Carcinoma in the Capsule Around Breast Implants – The ASCO Post

Related:

FDA Report: 660 Cases of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Study: Long-term Outcomes of Silicone Breast Implants

 


Phase 2 RCT | Neoadjuvant–adjuvant pembrolizumab improves event-free survival vs. adjuvant-only therapy in advanced melanoma

6 Mar, 2023 | 14:11h | UTC

Summary:

This phase 2 clinical trial evaluated whether giving pembrolizumab before and after surgery (neoadjuvant-adjuvant therapy) would increase event-free survival in patients with resectable stage III or IV melanoma, compared to adjuvant therapy alone. The trial involved 313 patients, with 154 in the neoadjuvant-adjuvant group and 159 in the adjuvant-only group.

At a median follow-up of 14.7 months, the neoadjuvant-adjuvant group had significantly longer event-free survival than the adjuvant-only group, with similar rates of adverse events between groups, suggesting that pembrolizumab given both before and after surgery may be an effective treatment option for these patients.

 

Article: Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Neoadjuvant immunotherapy improves outlook in high-risk melanoma – MD Anderson Cancer Center

 

Commentary on Twitter

 


RCT | Oral nicotinamide does not reduce skin cancer incidence in organ-transplant recipients

6 Mar, 2023 | 14:07h | UTC

Summary:

This article discusses a phase 3 clinical trial investigating whether oral nicotinamide (vitamin B3) effectively prevents skin cancer in organ transplant recipients.

The study enrolled 158 participants who had at least two keratinocyte cancers in the past five years, with 79 assigned to the nicotinamide group and 79 to the placebo group.

After 12 months, the two groups had no significant differences in the number of squamous-cell and basal-cell carcinomas, or actinic keratoses. Adverse events and changes in blood or urine laboratory variables were also similar in the two groups.

 

Article: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Oral Nicotinamide Not Beneficial in Preventing Skin Cancer in Organ Transplant Recipients – Dermatology Times

Related Study: A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention – New England Journal of Medicine

 


SR | Neoadjuvant treatment for stage III and IV cutaneous melanoma

3 Mar, 2023 | 13:32h | UTC

Neoadjuvant treatment for stage III and IV cutaneous melanoma – Cochrane Library

Summary: What are the benefits and risks of neoadjuvant treatment (drug treatment prior to surgery to remove a tumour) for melanoma, a type of skin cancer? – Cochrane Library

 


Consensus Paper | Revision of classification system for reporting on skin biopsies of melanocytic lesions

15 Jan, 2023 | 20:17h | UTC

Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement – JAMA Network Open

Commentaries: 

Classification system for reporting on skin biopsies of melanocytic lesions – University of California – Los Angeles Health Sciences

MPATH-Dx Version 2.0 Simplifies Classification of Melanoma – HealthDay

 

Commentary on Twitter

 


RCT | Tumor-infiltrating lymphocyte therapy vs. Ipilimumab in advanced melanoma.

8 Dec, 2022 | 12:51h | UTC

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Patient’s own immune cells effective as living medicine for melanoma – Netherlands Cancer Institute

 


Skin cancer in solid organ transplant recipients: a review for the non-dermatologist.

27 Nov, 2022 | 22:02h | UTC

Skin Cancer in Solid Organ Transplant Recipients: A Review for the Nondermatologist – Mayo Clinic Proceedings

 


Single-arm P2 study | Neoadjuvant relatlimab and nivolumab in resectable melanoma.

8 Nov, 2022 | 12:11h | UTC

Neoadjuvant relatlimab and nivolumab in resectable melanoma – Nature

News Release: Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma – MD Anderson News Release

 

Commentary on Twitter

 


RCT | Dabrafenib and Trametinib vs. Nivolumab and Ipilimumab for patients with advanced BRAF-mutant melanoma.

1 Nov, 2022 | 12:06h | UTC

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 – Journal of Clinical Oncology

News Release: Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy – Georgetown University Medical Center

Commentary: Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma – HealthDay

 


RCT | Adjuvant Nivolumab plus Ipilimumab vs. Nivolumab alone in patients with resected Stage IIIB-D or Stage IV melanoma.

30 Sep, 2022 | 12:33h | UTC

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) – Journal of Clinical Oncology

 


Phase 2 RCT | Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.

19 Sep, 2022 | 12:32h | UTC

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial – The Lancet (free registration required for full-text)

Commentary: Dual checkpoint inhibitor blockade shows promise as first-line and salvage therapy for Merkel cell carcinoma patients – H. Lee Moffitt Cancer Center & Research Institute

 


Phase 2 RCT | Sequencing of Ipilimumab plus Nivolumab and Encorafenib plus Binimetinib for untreated BRAF-mutated metastatic melanoma.

14 Sep, 2022 | 13:01h | UTC

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma – OncLive

 

Commentary on Twitter

 


Phase 2 single-arm study | Neoadjuvant Cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.

13 Sep, 2022 | 13:11h | UTC

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC – Cancer Network

 

Commentary on Twitter

 


RCT | Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma.

13 Sep, 2022 | 13:03h | UTC

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma – NEJM Evidence

 


Phase 2 RCT | Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease.

11 Sep, 2022 | 22:25h | UTC

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial – The Lancet

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.